Results 171 to 180 of about 117,631 (302)

Diversifying the triquinazine scaffold of a Janus kinase inhibitor. [PDF]

RSC Med Chem
Mulliri K, Meier K, Feuchter JD, Javor S, Meirelles MA, Reymond JL.   +5 more
europepmc   +1 more source

Janus kinase inhibitors in giant cell arteritis: unmet needs and new challenges. [PDF]

Reumatologia
Gkouvi A, Patrikiou E, Grammatikopoulou MG, Bogdanos DP.   +3 more
europepmc   +1 more source

Identification of two tyrosine kinase like proteins as important modulators of the STATc-mediated response to hyperosmolarity [PDF]

, 2013
Vu, Linh Hai
core  

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Janus Kinase Inhibitor Upadacitinib in Elderly-Onset Rheumatoid Arthritis With Hip Osteoarthritis: A Case Report. [PDF]

Am J Case Rep
Sanji Y, Matsushita I, Takahashi E, Fukui M, Kitajima H, Kaneuji A.   +5 more
europepmc   +1 more source

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon   +13 more
wiley   +1 more source

Emerging role of Janus kinase inhibitors in ulcerative colitis management. [PDF]

World J Gastrointest Pharmacol Ther
Ahsan MU, Sajid SL, Balach R, Daniyal M, Ain NU, Mudasir M.   +5 more
europepmc   +1 more source

Three Janus kinase inhibitors in ulcerative colitis: is upadacitinib taking the lead? [PDF]

Intest Res
Jung YS.
europepmc   +1 more source

Integrated proteomic and metabolomic profiling reveals sex‐stratified biomarkers predicting chronicity in paediatric primary immune thrombocytopenia

British Journal of Haematology, EarlyView.
Construction of the immune thrombocytopenia (ITP) chronicity prediction model was based on sex‐stratified multi‐omics analysis, identifying key sex‐specific predictors (intercellular adhesion molecule‐1 [ICAM‐1] and biopterin in males; actin, alpha 2, smooth muscle, aorta [ACTA‐2] and N6‐acetyl‐L‐lysine in females).
Yuanyuan Xue, Rongrong Zhang, Dongmei Liang, Yupeng Xu, Zhaofang Tian, Xiaohong Dai, Wei Xu, Qingqing Cao, Haiyan Zhu, Yun Wang, Yufang Yuan   +10 more
wiley   +1 more source

Selective Janus kinase inhibitors exhibit different effects in murine immune aplastic anemia. [PDF]

Hemasphere
Durrani J, Feng X, Wu Z, Gao S, Manley AL, Wu L, Glass J, Patel BA, Chen J, Young NS, Groarke EM.   +10 more
europepmc   +1 more source